RENEE RHEM: Open Payments
NPI 1346509239 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,330 in 130 payments from 18 companies in 2025. Trend: 2023 $2,566 · 2024 $2,580 · 2025 $4,330
Food & beverage: $4,235Education: $95
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 19 | $934 |
| AstraZeneca Pharmaceuticals LP | 14 | $661 |
| CSL Behring | 23 | $635 |
| GlaxoSmithKline, LLC. | 20 | $481 |
| Galderma Laboratories, L.P. | 10 | $294 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $237 |
| Novartis Pharmaceuticals Corporation | 6 | $227 |
| Ionis Pharmaceuticals, Inc. | 12 | $139 |
| Organon LLC | 2 | $137 |
| ConvaTec Inc. | 1 | $135 |
Products named: DUPIXENT, TEZSPIRE, Haegarda, NEMLUVIO, Andembry, NUCALA, NEFFY, FASENRA.
Industry payments across NY — which companies pay providers there.
